T. Rowe Price Associates’s Fulgent Genetics FLGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $412K | Buy |
20,711
+1,104
| +6% | +$22K | ﹤0.01% | 2390 |
|
|
2025
Q1 | $332K | Buy |
19,607
+942
| +5% | +$16K | ﹤0.01% | 2419 |
|
|
2024
Q4 | $345K | Buy |
18,665
+3,747
| +25% | +$69.3K | ﹤0.01% | 2438 |
|
|
2024
Q3 | $325K | Buy |
14,918
+56
| +0.4% | +$1.22K | ﹤0.01% | 2442 |
|
|
2024
Q2 | $292K | Buy |
14,862
+601
| +4% | +$11.8K | ﹤0.01% | 2428 |
|
|
2024
Q1 | $310K | Buy |
14,261
+3,458
| +32% | +$75.2K | ﹤0.01% | 2418 |
|
|
2023
Q4 | $313K | Buy |
10,803
+1,448
| +15% | +$42K | ﹤0.01% | 2356 |
|
|
2023
Q3 | $251K | Buy |
9,355
+351
| +4% | +$9.42K | ﹤0.01% | 2407 |
|
|
2023
Q2 | $334K | Buy |
9,004
+1,221
| +16% | +$45.3K | ﹤0.01% | 2309 |
|
|
2023
Q1 | $243K | Buy |
7,783
+836
| +12% | +$26.1K | ﹤0.01% | 2440 |
|
|
2022
Q4 | $207K | Buy |
6,947
+316
| +5% | +$9.42K | ﹤0.01% | 2517 |
|
|
2022
Q3 | $253K | Buy |
6,631
+1,378
| +26% | +$52.6K | ﹤0.01% | 2452 |
|
|
2022
Q2 | $286K | Buy |
5,253
+620
| +13% | +$33.8K | ﹤0.01% | 2453 |
|
|
2022
Q1 | $289K | Buy |
4,633
+1,411
| +44% | +$88K | ﹤0.01% | 2555 |
|
|
2021
Q4 | $324K | Sell |
3,222
-3,533
| -52% | -$355K | ﹤0.01% | 2568 |
|
|
2021
Q3 | $608K | Sell |
6,755
-2
| -0% | -$180 | ﹤0.01% | 2282 |
|
|
2021
Q2 | $623K | Buy |
6,757
+1,843
| +38% | +$170K | ﹤0.01% | 2276 |
|
|
2021
Q1 | $475K | Buy |
+4,914
| New | +$475K | ﹤0.01% | 2387 |
|